FDA Approves Guardant360 CDx for BRAF-Mutant Colorectal Cancer
Guardant Health’s Guardant360 CDx is now FDA-approved to identify BRAF V600E-mutant colorectal cancer patients, helping guide targeted therapy quickly with a simple blood test.
NOTRELOAD AI
Abbott Laboratories Stock Plunges on Nutrition Division Struggles and Weak Guidance
Abbott (ABT) stock fell 8% after missing Q4 earnings expectations, with nutrition sales dropping 8.9% due to lower volumes and strategic price cuts on baby formula and supplements.
Tempest Therapeutics Upgraded to Buy After Strategic CAR-T Acquisition
H.C. Wainwright upgrades Tempest Therapeutics to Buy, citing a smart CAR-T acquisition that extends cash runway and strengthens its pipeline.
Corcept's Experimental Drug Shows Promise in Extending Life for Ovarian Cancer Patients
Corcept Therapeutics' (CORT) relacorilant combined with chemotherapy reduced death risk by 35% in platinum-resistant ovarian cancer patients, with FDA decision expected July 2026.
Janux Therapeutics Partners with Bristol Myers Squibb in Major Cancer Drug Deal
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
GE Aerospace Q4 Beats Expectations But Growth Slows
GE Aerospace's Q4 2025 results exceeded Wall Street forecasts with strong commercial engine performance, though revenue growth is decelerating. Stock initially surged then fell 3%.